Boswellia frereana suppresses HGF-mediated breast cancer cell invasion and migration through inhibition of c-Met signalling

被引:22
作者
Parr, Christian [1 ]
Ali, Ahmed Y. [1 ]
机构
[1] Connect Tissue Labs, Sch Biosci, Sir Martin Evans Bldg, Cardiff, S Glam, Wales
关键词
Boswellia frereana; Breast cancer; Hepatocyte growth factor; c-Met; Invasion; Migration; Metastasis; HEPATOCYTE GROWTH-FACTOR; TUMOR-GROWTH; PHASE-II; RECEPTOR; COMBINATION; ACTIVATION; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; METASTASIS;
D O I
10.1186/s12967-018-1660-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Hepatocyte growth factor (HGF) plays a pivotal role in breast cancer cell motility, invasion and angiogenesis. These pro-metastatic events are triggered through HGF coupling and activation of the c-Met receptor. Reports have demonstrated that HGF/c-Met signalling plays an important part in breast cancer progression and that their expression is linked to poor patient outcome. In the present study, we investigated the anti-metastatic potential of an extract from traditional Somalian frankincense, Boswellia frereana, on human breast cancer cells. In addition, we also examined the effect of this Boswellia frereana extract (BFE) upon HGF-mediated stimulation of the c-Met receptor. Methods: Two triple negative human breast cancer cell lines, BT549 and MDA-MB-231, were utilised in the study to examine the effect of BFE on tumour cell proliferation, migration, matrix-adhesion, angiogenesis and invasion. Cell migration was investigated using a Cell IQ time-lapsed motion analysis system; while tumour cell-matrix adhesion, angiogenesis and invasion were assessed through Matrigel-based in vitro assays. Breast cancer cell growth and spheroid formation was examined through proliferation assay and 3D non-scaffold cell culture techniques. Western Blotting was employed to determine the phosphorylation status of the c-Met receptor tyrosine kinase following BFE treatment and subsequent HGF stimulation. Results: Following HGF treatment, the breast cancer cells displayed a significant increase in migration, matrix adhesion, vessel/tubule formation, invasion and c-Met activation. HGF did not appear to have any bearing on the proliferation rate or spheroid formation of these breast cancer cells. The addition of the BFE extract quenched the HGF-enhanced migratory, angiogenic and invasive potential of these cells. Further study revealed that BFE inhibited c-Met receptor tyrosine kinase phosphorylation within these breast cancer cells. Conclusions: Our findings reveal that BFE was able to significantly suppress the influence of HGF in breast cancer cell motility and invasion in vitro, through the ability of BFE to reduce HGF/c-Met signalling events. Therefore, these results indicate that BFE could play a novel role in the treatment of breast cancer.
引用
收藏
页数:12
相关论文
共 48 条
[1]  
[Anonymous], BMJ
[2]   Epithelial to Mesenchymal Transition Promotes Breast Cancer Progression via a Fibronectin-dependent STAT3 Signaling Pathway [J].
Balanis, Nikolas ;
Wendt, Michael K. ;
Schiemann, Barbara J. ;
Wang, Zhenghe ;
Schiemann, William P. ;
Carlin, Cathleen R. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (25) :17954-17967
[3]   Boswellia frereana (Frankincense) Suppresses Cytokine-Induced Matrix Metalloproteinase Expression and Production of Pro-Inflammatory Molecules in Articular Cartilage [J].
Blain, Emma J. ;
Ali, Ahmed Y. ;
Duance, Victor C. .
PHYTOTHERAPY RESEARCH, 2010, 24 (06) :905-912
[4]   FIBROBLAST-MEDIATED ACCELERATION OF HUMAN EPITHELIAL TUMOR-GROWTH INVIVO [J].
CAMPS, JL ;
CHANG, SM ;
HSU, TC ;
FREEMAN, MR ;
HONG, SJ ;
ZHAU, HE ;
VONESCHENBACH, AC ;
CHUNG, LWK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (01) :75-79
[5]   Treatment of triple negative breast cancer (TNBC): current options and future perspectives [J].
De Laurentiis, M. ;
Cianniello, D. ;
Caputo, R. ;
Stanzione, B. ;
Arpino, G. ;
Cinieri, S. ;
Lorusso, V. ;
De Placido, S. .
CANCER TREATMENT REVIEWS, 2010, 36 :S80-S86
[6]   Triple-negative breast cancer: Clinical features and patterns of recurrence [J].
Dent, Rebecca ;
Trudeau, Maureen ;
Pritchard, Kathleen I. ;
Hanna, Wedad M. ;
Kahn, Harriet K. ;
Sawka, Carol A. ;
Lickley, Lavina A. ;
Rawlinson, Ellen ;
Sun, Ping ;
Narod, Steven A. .
CLINICAL CANCER RESEARCH, 2007, 13 (15) :4429-4434
[7]   Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer [J].
Dieras, V. ;
Campone, M. ;
Yardley, D. A. ;
Romieu, G. ;
Valero, V. ;
Isakoff, S. J. ;
Koeppen, H. ;
Wilson, T. R. ;
Xiao, Y. ;
Shames, D. S. ;
Mocci, S. ;
Chen, M. ;
Schmid, P. .
ANNALS OF ONCOLOGY, 2015, 26 (09) :1904-1910
[8]   Triple-Negative Breast Cancer A Short Review [J].
Elias, Anthony D. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2010, 33 (06) :637-645
[9]   A lipoxygenase inhibitor in breast cancer brain metastases [J].
Flavin, D. F. .
JOURNAL OF NEURO-ONCOLOGY, 2007, 82 (01) :91-93
[10]   Met receptor tyrosine kinase: enhanced signaling through adapter proteins [J].
Furge, KA ;
Zhang, YW ;
Vande Woude, GF .
ONCOGENE, 2000, 19 (49) :5582-5589